Ipsen Announces Publication in the Lancet Neurology of the Results of the Phase III Randomized Study (NCT01313299) Showing Efficacy and Safety of DysportÂ® (abobotulinumtoxinA) in Adult Patients with Upper Limb Spasticity (U